Scarica l'app Stockscreener
395.92
2.10%
8.15
Dopo l'orario di chiusura:
395.90
-0.02
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $430 From $530, Maintains Buy Rating - MarketScreener
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market - Yahoo Finance
The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX) - Seeking Alpha
Vertex HQ refinanced for $1 billion - The Business Journals
Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point - Yahoo Finance
Vertex Pharmaceuticals: A Biotech Powerhouse Poised for Rebound After Oversold Correction - AInvest
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) (NASDAQ:VRTX) - Seeking Alpha
Goldman Sachs reiterates Buy rating on Vertex stock, citing diversification By Investing.com - Investing.com South Africa
The week in pharma: action, reaction and insight – week to August 8 - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN
Vertex unveils positive study data for CF triple-combination regimens; shares jump - FirstWord Pharma
KOL Views: Vertex's triplet data exceed expectations – implications for CF landscape - firstwordpharma.com
Vertex Analyst Rating Lowered by B of A Securities; VERX Stock Price Target Cut to $34.00 - AInvest
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com
Hedge Fund and Insider Trading News: Ken Griffin, DE Shaw, Bobby Jain, Jim Cramer, Rokos Capital Management, Point72 Asset Management, Vertex Pharmaceuticals Inc (VRTX), Galaxy Digital Inc (GLXY), and More - Insider Monkey
Vertex Pharmaceuticals Plunges 2.69%—Is This the Bottom for Vertex Pharmaceuticals? - AInvest
Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener
Stock Analysis | Vertex Pharmaceuticals OutlookNavigating Mixed Signals and Market Uncertainty - AInvest
Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com
RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener
Vertex Pharmaceuticals Executives Make Significant Stock Purchases - TradingView
$1B Deal: RMR Group Refinances Vertex Pharma's Boston HQ with 15-Year Lease Extension - Stock Titan
Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest
The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media
Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN
Vertex’s Journavx successor culled after falling short in Phase II trial - Clinical Trials Arena
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - MSN
Vertex Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks
Vertex falls after FDA doubts broad use of chronic pain drug - The Boston Globe
Vertex Pharmaceuticals Reports 12% Revenue Increase in Q2 2025 - The Globe and Mail
Growing, pain: Journavx on the move as Vertex reports 2Q hitches - BioWorld MedTech
Vertex Pharmaceuticals Halts Development of VX-993 After Phase II Trial Fails to Show Pain Relief Benefit - geneonline.com
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today - TradingView
Vertex Pharmaceuticals stock hits 52-week low at $377.78 - Investing.com
Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga
Cantor Equity Partners, Inc. shares fall 2.41% intraday as Vertex Pharmaceuticals' price targets are adjusted by multiple analysts. - AInvest
Vertex stock price target lowered to $478 at H.C. Wainwright on pain program setbacks - Investing.com Australia
Vertex Pharmaceuticals: A Long-Term Growth Story Fueled by Financial Discipline and Pipeline Breakthroughs - AInvest
Vertex’s strong quarter unable to undo pain from VX-993 woes - The Pharma Letter
VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial - TradingView
Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain - Patient Care Online
Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq
Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study - MedCity News
Vertex Pharmaceuticals Stock Falls 15% After Failed Drug TrialNews and Statistics - IndexBox
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal - Yahoo Finance
Vertex Pharmaceuticals' Q2 2025 Earnings and JOURNAVX Strategy Discrepancies: Assessing Long-Term Viability Amid Short-Term Volatility - AInvest
Vertex Pharmaceuticals: Navigating Short-Term Setbacks to Unlock Long-Term Value in a High-Stakes Biotech Landscape - AInvest
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):